Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

Non-alcoholic fatty liver disease (NAFLD) is common, affecting approximately 25% of the
general population. The evidence base for the investigation and management of NAFLD is …

How to assess efficacy of interventions. In clinical practice, and particularly among those
who appear to have mild liver disease, it may be sufficient to note changes (normalization) of …

Background The liver has a critical role in the metabolism of glucose and lipids. Chronic
hepatitis B virus (HBV) or hepatitis C virus (HCV) infection leads to a spectrum of liver …

Hepatitis C virus (HCV) is a leading cause of chronic liver disease, including chronic
hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Hepatitis C infection associates …

Chronic hepatitis C, attributed to infection with hepatitis C virus (HCV), is a global health
problem. The overall prevalence of viral hepatitis worldwide is estimated to be 3–5% with …

Background Rising rates of obesity, diabetes mellitus (DM), and nonalcoholic fatty liver
disease (NAFLD) among chronic hepatitis C (HCV) patients may contribute to higher …

Abstract The Asian Pacific Association for the Study of the Liver (APASL) convened an
international working party on “APASL consensus statements and recommendations for …

The overall prevalence of steatosis in patients with Hepatitis C virus (HCV) chronic infection
is 55.5%(range 34.8–81.2%). This is a two to threefold increase compared with the …

BACKGROUND/AIMS: Hepatitis C virus genotype-3a (HCV-3a) is directly linked to steatosis
development. We studied the effects of HCV-3a core protein on the promoter activity of fatty …